Cargando…
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed. We employed proximity extension-based assays to measure 665 proteins in the cerebrospinal fluid (CSF) from patients with DLB (n = 109), Alzheimer´s disease (AD, n = 235) and cognitively un...
Autores principales: | del Campo, Marta, Vermunt, Lisa, Peeters, Carel F. W., Sieben, Anne, Hok-A-Hin, Yanaika S., Lleó, Alberto, Alcolea, Daniel, van Nee, Mirrelijn, Engelborghs, Sebastiaan, van Alphen, Juliette L., Arezoumandan, Sanaz, Chen-Plotkin, Alice, Irwin, David J., van der Flier, Wiesje M., Lemstra, Afina W., Teunissen, Charlotte E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499811/ https://www.ncbi.nlm.nih.gov/pubmed/37704597 http://dx.doi.org/10.1038/s41467-023-41122-y |
Ejemplares similares
-
Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
por: Hok‐A‐Hin, Yanaika S., et al.
Publicado: (2023) -
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019) -
Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2023) -
Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020) -
Disease progression in dementia with Lewy bodies: A longitudinal study on clinical symptoms, quality of life and functional impairment
por: van de Beek, Marleen, et al.
Publicado: (2022)